About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia

Clinicaltrials.gov identifier NCT03938363

Recruitment Status Recruiting

First Posted May 6, 2019

Last update posted March 29, 2021

Study Description

Brief summary:

Efficient gait requires effective postural control, both static and dynamic. Hence, postural disorders may affect gait. Yet, very little is known about the specific effects of focal postural disorders such as cervical dystonia (CD) and blepharospasm (BS) on patients' mobility. The present research therefore aims at analyzing gait characteristics in patients presenting with these conditions in order to document possible gait alterations. In addition, the investigators will explore the effect of botulinum toxin treatment, which the most frequently used therapeutic option, on the patients' gait characteristics. Indeed, while the treatment improves both dystonia and pain, and therefore quality of life, its influence on gait is presently unknown. the investigators aim at filling this knowledge gap

  • Condition or Disease:Blepharospasm
    Cervical Dystonia, Primary
  • Intervention/Treatment: Other: Treadmill
    Drug: Botulinum Toxin injection
    Diagnostic Test: Severity scale of the disease
  • Phase: N/A
Detailed Description

This is a pilot monocentric, non-randomized, controlled study. The total duration of the project is 24 months. For each patient, the total duration of the study will be one month. The primary goal is to study gait parameters in patients with focal dystonia (CD and BS) before and after botulinum toxin treatment. The secondary goal is to study interactions between dystonia severity and gait disorders, if gait disorders are objectified. The investigators will also examine whether botulinum toxin treatment affects gait parameters. The main dependent variable regarding gait analysis will be gait velocity, as it is the most relevant functional variable for the patients. Gait velocity will be measured on the ground using the 10 Meter Walk Test (10MWT). Gait velocity will thereafter be adjusted to the treadmill to be the most comfortable. Spatial and temporal gait parameters will also be analyzed, namely: step frequency, step length, step length variability, gait asymmetry, and side with the shortest step length. To examine the influence of dystonia severity on gait parameters, the investigators will examine possible links between the gait parameters and dystonia severity as reflected by the global scores of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) for cervical dystonia and the Jankovic Rating Scale (JRS) for blepharospasm. In order to evaluate the effects of the botulinum toxin on gait parameters, the investigators will compare gait variables before and after toxin treatment in the patient groups. If gait parameters are influenced by the treatment, the investigators will compare the post treatment data with the data of the healthy control group. In addition, the investigators will perform a patient satisfaction scale (Patient Global Impression of Change) on the change of walking parameters. For this pilot, longitudinal, prospective, controlled study, the investigators will include two groups of 10 patients (patients with DC, patients with BS, naive or not about botulinum toxin treatment) and two groups of 10 age- and sex-matched healthy control subjects. After collecting demographical information, severity of dystonia will be assessed using the relevant Dystonia scale (for the patients' groups). Participants will then be shortly trained walking on a treadmill. Thereafter, they will be required to walk on a BIODEX treadmill enabling recording of all targeted gait parameters. For the patients' groups, gait parameters will be recorded both before and 4-5 weeks after the injection. At the firth visit, the duration of assessments and treatment for the patients will be about 1.5 hour. At the second visit, assessment will last about 30 minutes. To examine the influence of dystonia (CD, BS) on gait velocity and parameters, patients and matched healthy control data will be compared using the Mann-Whitney non parametric test. To examine the influence of botulinum toxin injection in each group of patients, data will be compared using the Wilcoxon test. Pearson correlation will be used to examine possible links between dystonia severity and gait parameters alterations. This study will contribute to improving our knowledge on the effects of focal dystonia on gait, thus enabling an improvement in the design of rehabilitation programs. It will also document the effect of botulinum toxin on gait, thus contributing to a better guidance of this treatment.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 40 participants
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Basic Science
  • Official Title: Analyse de la Marche de Patients Atteints de Dystonie Focale Avant et après Traitement Par Toxine Botulique
  • Actual Study Start Date: October 2019
  • Estimated Primary Completion Date: June 2021
  • Estimated Study Completion Date: December 2021
Arms and interventions
Arm Intervention/treatment
Experimental: Blepharospasm (BS)
Patients with blepharospasm
Other: Treadmill
Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups

Drug: Botulinum Toxin injection
injection of Botulinum Toxin in the two groups of CD and BS

Diagnostic Test: Severity scale of the disease
JRS for BS TWSTRS for CD
Experimental: Cervical Dystonia (CD)
Patients with cervical dystonia
Other: Treadmill
Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups

Drug: Botulinum Toxin injection
injection of Botulinum Toxin in the two groups of CD and BS

Diagnostic Test: Severity scale of the disease
JRS for BS TWSTRS for CD
Placebo Comparator: Healthy Control BS
BS age- and sex-matched healthy control subjects
Other: Treadmill
Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
Placebo Comparator: Healthy Control CD
CD age- and sex-matched healthy control subjects
Other: Treadmill
Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
Outcome Measures
  • Primary Outcome Measures: 1. gait velocity [ Time Frame: 5 minutes ]
    comfortable gait velocity on the treadmill
  • Secondary Outcome Measures: 1. step length variability [ Time Frame: 5 minutes ]
    registration on the treadmill
  • 2. step frequency [ Time Frame: 5 minutes ]
    registration on the treadmill
  • 3. step length [ Time Frame: 5 minutes ]
    registration on the treadmill
  • 4. step length asymmetry [ Time Frame: 5 minutes ]
    registration on the treadmill
  • 5. shortest step side [ Time Frame: 5 minutes ]
    registration on the treadmill
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

- speaking French, in the ability to understand clinical tests and explorations,

- in ability to move to the CHU Grenoble Alpes

- Diagnosis of cervical dystonia or isolated Blepharospasm,

- Absence of neurological or psychiatric disorders,

- Affiliation to a health insurance,

- Signed consent fo the subject.

Exclusion Criteria:

- Pregnant women (positive pregnancy test), parturient or breastfeeding

- Cervical dystonia or Blepharospasm of secondary origin

- subjects having benefited from deep brain stimulation,

- History of other pathologies that may lead to walking disorders, inability to walk
without technical assistance, inability to walk for more than 10 minutes,

- Subjects receiving botulinum toxin treatment for another cause.

Prohibited treatments and procedures:

- Antecedent of pathologies that may cause walking disorders

- Simultaneous participation in another Interventional study

- Subject in time of exclusion from another study

- Subject under guardianship or having curators (major protected)

- Subject under administrative or judicial supervision

- Subject not able to be contacted in case of emergency

Contacts and Locations
Contacts
Locations

France, Isere
CHU Grenoble Alpes
La Tronche

Sponsors and Collaborators

University Hospital, Grenoble

More Information